These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 31617141)

  • 1. Stiripentol: A Review in Dravet Syndrome.
    Frampton JE
    Drugs; 2019 Nov; 79(16):1785-1796. PubMed ID: 31617141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stiripentol : in severe myoclonic epilepsy of infancy (dravet syndrome).
    Plosker GL
    CNS Drugs; 2012 Nov; 26(11):993-1001. PubMed ID: 23018548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: A multicenter, open-label study in Japan.
    Inoue Y; Ohtsuka Y;
    Epilepsy Res; 2015 Jul; 113():90-7. PubMed ID: 25986195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group.
    Chiron C; Marchand MC; Tran A; Rey E; d'Athis P; Vincent J; Dulac O; Pons G
    Lancet; 2000 Nov; 356(9242):1638-42. PubMed ID: 11089822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence.
    Inoue Y; Ohtsuka Y;
    Epilepsy Res; 2014 May; 108(4):725-31. PubMed ID: 24630050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do children with Dravet syndrome continue to benefit from stiripentol for long through adulthood?
    Chiron C; Helias M; Kaminska A; Laroche C; de Toffol B; Dulac O; Nabbout R; An I
    Epilepsia; 2018 Sep; 59(9):1705-1717. PubMed ID: 30132836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stiripentol: new preparation. Severe myoclonic epilepsy of infancy: promising.
    Prescrire Int; 2005 Apr; 14(76):57-9. PubMed ID: 15875342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stiripentol (Diacomit) for Dravet syndrome.
    Med Lett Drugs Ther; 2021 Mar; 63(1620):e48-e50. PubMed ID: 33976090
    [No Abstract]   [Full Text] [Related]  

  • 9. Stiripentol in Dravet syndrome: results of a retrospective U.S. study.
    Wirrell EC; Laux L; Franz DN; Sullivan J; Saneto RP; Morse RP; Devinsky O; Chugani H; Hernandez A; Hamiwka L; Mikati MA; Valencia I; Le Guern ME; Chancharme L; de Menezes MS
    Epilepsia; 2013 Sep; 54(9):1595-604. PubMed ID: 23848835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and effectiveness of stiripentol in patients with Dravet syndrome: Interim report of a post-marketing surveillance study in Japan.
    Yamada M; Suzuki K; Matsui D; Inoue Y; Ohtsuka Y
    Epilepsy Res; 2021 Feb; 170():106535. PubMed ID: 33388609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current therapeutic procedures in Dravet syndrome.
    Chiron C
    Dev Med Child Neurol; 2011 Apr; 53 Suppl 2():16-8. PubMed ID: 21504427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stiripentol efficacy and safety in Dravet syndrome: a 12-year observational study.
    Myers KA; Lightfoot P; Patil SG; Cross JH; Scheffer IE
    Dev Med Child Neurol; 2018 Jun; 60(6):574-578. PubMed ID: 29473155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marked efficacy of combined three-drug therapy (Sodium Valproate, Topiramate and Stiripentol) in a patient with Dravet syndrome.
    Morimoto M; Shimakawa S; Hashimoto T; Kitaoka T; Kyotani S
    J Clin Pharm Ther; 2018 Aug; 43(4):571-573. PubMed ID: 29265387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stiripentol: A Novel Antiseizure Medication for the Management of Dravet Syndrome.
    Buck ML; Goodkin HP
    Ann Pharmacother; 2019 Nov; 53(11):1136-1144. PubMed ID: 31167540
    [No Abstract]   [Full Text] [Related]  

  • 15. Stiripentol for the treatment of seizures in Dravet syndrome.
    Eschbach K; Knupp KG
    Expert Rev Clin Pharmacol; 2019 May; 12(5):379-388. PubMed ID: 31017478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis.
    Guerrini R; Chiron C; Vandame D; Linley W; Toward T
    Epilepsia Open; 2024 Apr; 9(2):689-703. PubMed ID: 38427284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacologic treatment of Dravet syndrome.
    Chiron C; Dulac O
    Epilepsia; 2011 Apr; 52 Suppl 2():72-5. PubMed ID: 21463285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost-Utility Analysis.
    Elliott J; McCoy B; Clifford T; Wells GA; Coyle D
    Pharmacoeconomics; 2018 Oct; 36(10):1253-1261. PubMed ID: 29761351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stiripentol for the treatment of seizures associated with Dravet syndrome.
    Chiron C
    Expert Rev Neurother; 2019 Apr; 19(4):301-310. PubMed ID: 30900478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Starting stiripentol in adults with Dravet syndrome? Watch for ammonia and carnitine.
    Zulfiqar Ali Q; Marques P; Selvarajah A; Tabarestani S; Sadoway T; Andrade DM
    Epilepsia; 2020 Nov; 61(11):2435-2441. PubMed ID: 33084037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.